The Global Rise of Multiomics Market is Driving Healthcare Transformation

The Global Rise of Multiomics Market is Driving Healthcare Transformation

The global rise of multiomics is allowing researchers to unlock deeper biological insights by combining multiple layers of "omics" data such as genomics, proteomics and metabolomics. Multiomics is enabling more personalized treatment options by providing a comprehensive view of biological systems at the molecular level.

Multiomics utilizes high-throughput technologies to collect and analyze vast amounts of molecular data from biosamples. It helps characterize biological states and changes that occur due to disease, environment or drug response. Multiomics goes beyond single "omic" approaches by integrating multiple types of omics data to gain a systems-level understanding. This integrated approach improves disease diagnosis, prognosis and guides more effective therapeutic strategies.

The Global Multiomics Market is estimated to be valued at US$ 7.65 Bn in 2024 and is expected to exhibit a CAGR of 15% over the forecast period from 2024 to 2031.

Rapid advances in multiomics technologies and their wide applications across various therapeutic areas are fueling market growth.

Key Takeaways

Key players operating in the global multiomics market are BD, Thermo Fisher Scientific Inc., Illumina, Inc, Danaher, PerkinElmer Inc., Shimadzu Corporation, Bruker, QIAGEN, Agilent Technologies, Inc., and BGI.

Growing demand for personalized medicine and molecular diagnostics is driving increased adoption of multiomics approach. Multiomics helps develop tailored treatment regimens by identifying disease subtypes and predictive biomarkers.

Leading diagnostics players are expanding their Global Multiomics Market Size portfolios through partnerships and acquisitions to tap emerging markets. Increasing research collaborations between pharma companies and academic institutes are also contributing to the global expansion of the multiomics market.

Market Key Trends

Integration of artificial intelligence and machine learning is emerging as a key trend in the multiomics market. AI and ML tools help analyze large and complex multiomics datasets to gain novel insights. They facilitate automated biomarker detection, outcome prediction and drug response analysis. This helps accelerate the drug discovery and development process. Adoption of cloud-based platforms for centralized multiomics data management and analysis is also growing. Cloud solutions ensure scalability, collaborative access and cost-effective analysis of large "omics" datasets. Overall, multiomics combined with AI/ML and cloud computing offers tremendous potential for advanced personalized healthcare applications.

Porter's Analysis
Threat of new entrants: High capital requirement and strong presence of key players like BD, Thermo Fisher Scientific Inc., Illumina, Inc make it difficult for new players to enter.
Bargaining power of buyers: Buyers have high bargaining power due to availability of substitution and presence of several players offering multiomics solutions.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to differentiated products and technologies offered by them. However, presence of alternative suppliers balances their power.
Threat of new substitutes: Threat of substitution is moderate as it requires huge investments in R&D to develop new substitutes for existing multiomics solutions.
Competitive rivalry: Intense competition exists among key players to increase their market share by expanding their product portfolio and geographic presence through collaborations and partnerships.

North America dominates the global multiomics market primarily due to heavy funding for genomic and proteomic research, presence of major market players, increasing awareness about personalized medicines and rising focus on precision medicine in the region. Asia Pacific is anticipated to grow at fastest CAGR during forecast period driven by increasing healthcare expenditure, large patient population and shifting of pharmaceutical and CROs from developed markets to emerging Asian countries.
​
Get more insights on – Global Multiomics Market
 
Explore Related Articles- Pour Point Depressant Market

About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)